GlobeNewsWire
24 Nov 2025, 18:59 UTC · 43w ago
Verdict
Headline leans bearish. We score SMTI −0.80 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Sanara MedTech Inc. (SMTI) has discontinued operations of its Tissue Health Plus division as part of a strategic realignment.
More negative than 95% of claims this week
Holzer & Holzer, LLC is investigating whether Sanara MedTech Inc. complied with federal securities laws following the realignment announcement.
Continue reading
5 related stories
More negative than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 87% of claims this week
Which stocks this story touches
More negative than 85% of ticker scores this week
The company is under investigation by a law firm following a stock price drop and the discontinuation of a business unit.
More negative than 79% of ticker scores this week
The company is being investigated by a law firm regarding compliance with federal securities laws.
More negative than 79% of ticker scores this week
The company is being investigated by a law firm regarding compliance with federal securities laws.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
17m ago
+80.4%
Price is moving against the score
$35.15 vs $19.48 close before publication (Nov 21) · not market-adjusted
SMTI chart →
